101530-10-3
中文名称
拉诺康唑
英文名称
Lanoconazole
CAS
101530-10-3
分子式
C14H10ClN3S2
MDL 编号
MFCD00865590
分子量
319.83
MOL 文件
101530-10-3.mol
更新日期
2025/10/17 19:48:02
101530-10-3 结构式
基本信息
中文别名
[4-(2-氯苯基)-1,3-亚二硫戊环-2-基]-2-咪唑-1-基-乙腈拉诺康唑
兰诺康唑
(±)-(E)-Α-[4-(2-氯苯基)-1,3-二硫戊烷-2-亚基]-1H-咪唑-1-乙腈
英文别名
[4-(2-chloro-phenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-yl-acetonitrileLANOCONAZOLE
(+-)-(e)-(4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene)-1-imidazolylacetonitri
(e)-alpha-(4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene)-1h-imidazole-1-aceton
1h-imidazole-1-acetonitrile,alpha-(4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene)
itrile
latoconazole
le
nnd-318
tjn-318
(E)-(+/-)-[4-(2-Chlorophenyl)-1,3-dithiolan-2-ylidene]-1H-imidazole-1-acetonitrile
1H-Imidazole-1-acetonitrile, a-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-, (aE)- (9CI)
1H-Imidazole-1-acetonitrile, a-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-, (E)-
1H-Imidazole-1-acetonitrile, a-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-, (E)-(+-)-
Astat
2-[4-(2-Chlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-yl-acetonitrile
(+-)-(E)-(4-(2-Chlorophenyl)-1,3-dithiolan-2-ylidene)-1-imidazolylacetonitrile
(E)-alpha-(4-(2-Chlorophenyl)-1,3-dithiolan-2-ylidene)-1H-imidazole-1-acetonitrile
1H-Imidazole-1-acetonitrile, alpha-(4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene)-, (E)-(+-)
(E)-2-[4-(2-Chlorophenyl)-1,3-dithiolane-2-ylidene]-2-(1-imidazolyl)acetonitrile
所属类别
药物: 抗病源性微生物药: 抗真菌感染药物物理化学性质
外观性状拉诺康唑(101530-10-3)为淡黄色结晶
熔点141.50C
沸点477.6±55.0 °C(Predicted)
密度1.43±0.1 g/cm3(Predicted)
储存条件2-8°C
溶解度可溶于氯仿（少许）、甲醇（少许）
酸度系数(pKa)3.76±0.10(Predicted)
形态neat
颜色白色
安全数据
制备方法
方法一
2-(1-咪唑基)乙腈与二硫化碳和氢氧化钾在二甲基甲酰胺中反应得连二硫酸酯的二钾盐，然后和1-(2-氯苯基)-1，2-二(甲磺酰氧基)乙烷环合。经硅胶柱层析分离(E)和(Z)异构体，而得拉诺康唑。常见问题列表
概述
拉诺康唑为咪唑类抗真菌药物，作用机制同其他咪唑类药物，主要通过抑制14-甲基羊毛甾醇的脱14-甲基阶段，从而达到抑制真菌细胞麦角固醇合成的目的而具有抗真菌作用。生物活性
Lanoconazole 是一种强效口服咪唑类抗真菌 (antifungal) 试剂，具有广谱的体内外抗真菌活性。Lanoconazole 通过抑制 sterol 14-alpha 去甲基酶，阻断真菌膜上的 ergosterol 生物合成，从而干扰 ergosterol 的生物合成。Lanoconazole 可用于皮肤真菌病和甲真菌病的研究。靶点
IC50: antifungal
体内研究
Lanoconazole (treatment for ear; 0.3%-3%; 6 days) dose‐dependently suppressesTPA-induced irritant dermatitis, suppresses the production of neutrophil chemotactic factors such as keratinocyte‐derived chemokine and macrophage inflammatory protein‐2, and inhibited neutrophil infiltration to the inflammation site.Lanoconazole (oral administration; 3, 10 or 30 mg/kg; once a day; 3 weeks) significantly inhibits C. neoformans compared with the saline control in normal mice. In addtion, it significantly reduces the growth of C. neoformans in the lungs and brains of MAIDS mice.
| Animal Model: | BALB/c mice |
| Dosage: | 0.3%-3% dosage |
| Administration: | Treatment for ear |
| Result: | Exhibited an inhibition effect of LCZ on ear swelling induced by topical application of TPA in mice. |
| Animal Model: | Four week old C57BL/6 mice infected intraperitoneally with LP-BM5 murine leukaemia virus |
| Dosage: | 3, 10 or 30 mg/kg |
| Administration: | Oral adminstration |
| Result: | Inhibited C. neoformans growth in both normal and C. neoformans -induced encephalitis MAIDS mice . |